Study on the efficacy and safety of reduced-fluence photodynamic therapy for chronic central serous chorioretinopathy
Phase 2
- Conditions
- chronic central serous chorioretinopathy
- Registration Number
- JPRN-UMIN000008819
- Lead Sponsor
- Kawasaki Medical School Hospital Department of Ophthalmology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
1) drug allergy to verteporfin 2) porphyria, or hypersensitivity to artificial illumination 3) macular diseases other than central serous chorioretinopathy 4) pregnant or expecting pregnancy 5) others, inappropriate case judged by investigator or subinvestigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method resolution of serous retinal detachment of 7 days, 1 month, 3 months, 6 months and 1 year after reduced-fluence photodynamic therapy
- Secondary Outcome Measures
Name Time Method 1) visual acuity 2) optical coherence tomography 3) fluorescein angiography 4) indocyanine green angiography evaluation time 1), 2): 7 days, 1 month, 3 months, 6 months, 1 year after RF-PDT 3), 4): 1 month, 3 months, 1 year after RF-PDT